Organization
Genentech, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Genentech, Inc.
... Exelixis, Inc. (NASDAQ:EXEL) today announced the presentation of updated results from the Genentech-sponsored phase 1b clinical trial of cobimetinib (COTELLIC®), an Exelixis-discovered MEK inhibitor, in ...
... FirstEnergy, FIS, Franklin Templeton Investments, Fred Hutch Cancer Research Institute, Gap Inc., Genentech, General Atlantic*, General Mills, Guardian Life Insurance, Harris Corporation, Herbalife Nutrition, Hewlett-Packard ...
... to announce they have been selected as an authorized provider of HEMLIBRA®, Genentech's new treatment product for patients diagnosed with hemophilia A with inhibitors. Chief ...
... Roche to its partner list for its CD47-targeted immuno-oncology candidate, with Roche’s Genentech unit agreeing to sponsor two trials of the antibody in combination with ...
... Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck & Co.(USA), Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, Asahi Kasei, Janssen, and Bayer all of which are active and ...
... patient's immune systems to defeat their cancer, today announced an agreement with Genentech Inc., a member of the Roche Group., for Genentech to sponsor two ...
... Genentech and Syndax have expanded their exploration of the effects of combining HDAC ...
... for assisting intervention with Zenyaku Kogyo Co., Ltd. in a lawsuit that Genentech Inc. filed to the Tokyo District Court as of December 28, 2017, ...
... With the April 2017 launch of Genentech's Ocrevus, the monoclonal antibody (mAb) disease-modifying therapy (DMT) class share of DMT-treated ...
... SNDX-6352 in multiple cancer indications, today announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the ...
... is anticipated to begin by year-end. Xenon has an ongoing collaboration with Genentech focused on developing novel inhibitors of Nav1.7 for the treatment of pain, ...
... example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)--which, at the time, had been studied in at least 400 ...
... example I focused on then was the cancer drug Avastin, developed by Genentech (now Roche)--which, at the time, had been studied in at least 400 ...
... after the company's acquisition by Sanofi Pasteur. FierceVaccines > Wendy Young, formerly Genentech's VP of discovery chemistry was promoted to SVP of small molecule discovery, ...
... lymphomas and solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are ...
... reporting the total following the series A is nearing $1 billion. RELATED: Genentech lays $310 million wager on BioNTech’s mRNA cancer vaccine platform Some of ...
... other diseases with high medical need. Its corporate partnerships include collaborations with Genentech, a member of the Roche Group, Eli Lilly and Company, Sanofi, Genmab ...
... comes after Arvinas recently doubled the size of its collaboration with Roche’s Genentech, which also focuses on PROTAC, rounding off a good few months for ...
... South San Francisco, CA - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
Want to see the full history on Genentech, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial